Diabetic Neuropathy - Pipeline Review, H2 2019

Diabetic Neuropathy - Pipeline Review, H2 2019



latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 11, 6, 2 and 15 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy - Overview
Diabetic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Angelini Group
Applied Therapeutics Inc
Arena Pharmaceuticals Inc
Bionevia Pharmaceuticals
Bol Pharma
Bristol-Myers Squibb Co
Calchan Ltd
Celularity Inc
Cleveland Diabetes Care Inc
Commence Bio Inc
CSPC Pharmaceutical Group Ltd
Exodos Life Sciences Limited Partnership
Glycadia Inc
GNT Pharma Co Ltd
Grifols SA
Grunenthal GmbH
Immune Pharmaceuticals Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Kineta Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Omeros Corp
Praetego Inc
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Inc
Sphaera Pharma Pte Ltd
WEX Pharmaceuticals Inc
Winsantor Inc
YD Life Science Co
Yuhan Corp
Zhejiang Pharmaceutical Co Ltd
Diabetic Neuropathy - Drug Profiles
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Diabetic Neuropathy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2019
Diabetic Neuropathy - Pipeline by Angelini Group, H2 2019
Diabetic Neuropathy - Dormant Projects, H2 2019
Diabetic Neuropathy - Dormant Projects, H2 2019 (Contd..1), H2 2019
Diabetic Neuropathy - Dormant Projects, H2 2019 (Contd..2), H2 2019
Diabetic Neuropathy - Discontinued Products, H2 2019

List Of Figures


Number of Products under Development for Diabetic Neuropathy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Diabetic Nephropathy - Pipeline Review, H1 2020

Diabetic Nephropathy - Pipeline Review, H1 2020 latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2020, provides an overview of the Diabetic Nephropathy (Metabolic Disorders)

USD 2000 View Report

Diabetic Retinopathy - Pipeline Review, H2 2019

Diabetic Retinopathy - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline

USD 2000 View Report

Optic Neuropathy - Pipeline Review, H1 2020

Optic Neuropathy - Pipeline Review, H1 2020 latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline

USD 2000 View Report

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Peripheral Neuropathy

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available